Extended prophylaxis of venous thromboembolism with idraparinux

New England Journal of Medicine

Volumn 357, Issue 11, 2007, Pages 1105-1112

  Buller, Harry R ^a,b   Cohen, Ander T ^c   Davidson, Bruce ^d   Decousus, Hervé ^e   Gallus, Alex S ^f   Gent, Michael ^g   Pillion, Gerard ^h   Piovella, Franco ⁱ   Prins, Martin H ^j,k   Raskob, Gary E ^l  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITÉ JEAN MONNET   (France)

^f FLINDERS MEDICAL CENTRE   (Australia)

^g MCMASTER UNIVERSITY   (Canada)

^h SANOFI   (France)

ⁱ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^j MAASTRICHT UNIVERSITY   (Netherlands)

^k MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; IDRAPARINUX; PLACEBO; WARFARIN; BLOOD CLOTTING FACTOR 10A; OLIGOSACCHARIDE; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG ANTAGONISM; FOLLOW UP; KAPLAN MEIER METHOD; LUNG EMBOLISM; MIDDLE AGED; MORTALITY; SUBCUTANEOUS DRUG ADMINISTRATION; VEIN THROMBOSIS;

AGED; ANTICOAGULANTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FACTOR XA; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; OLIGOSACCHARIDES; PULMONARY EMBOLISM; RECURRENCE; TREATMENT OUTCOME; VENOUS THROMBOSIS; VITAMIN K;

EID: 34548712332     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa067703     Document Type: Article

References (14)

1. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
2. The PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005;112:416-22.
3. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
4. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-9.
5. Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
6. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006;1:CD001367.
7. Büller HR, Agnelli GA, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl 3:401S-428S. [Erratum, Chest 2005;127:416.]
8. Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and longacting pentasaccharide. Blood 1998;91:4197-205.
9. The PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J Thromb Haemost 2004;2:47-53. [Erratum, J Thromb Haemost 2004;2:540.]
10. The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357:1094-104.
11. Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-73.
12. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702.
13. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-34.
14. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.